Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial

Table 3 Malaria infection and anaemia at delivery, by treatment groups

Outcome	ITT analysis						PP analysis
	Control		Intervention		Risk ratio	P	Control		Intervention		Risk ratio	P
	(SPCQ and placebo)		(SPAZ)		(95% CI)		(SPCQ and placebo)		(SPAZ)		(95% CI)
Peripheral blood (light microscopy)
All infections	40/1,022	(3.9)	23/1,023	(2.3)	0.57 (0.35–0.95)	0.029	39/962	(4.1)	22/972	(2.3)	0.56 (0.33–0.93)	0.024
P. falciparum	29	(2.8)	18	(1.8)	0.62 (0.35–1.11)	0.104	28	(2.9)	17	(1.8)	0.60 (0.33–1.09)	0.090
P. vivax	11	(1.1)	5	(0.5)	0.45 (0.16–1.30)	0.142	11	(1.1)	5	(0.5)	0.45 (0.16–1.29)	0.127
Placental blood (light microscopy)
All infections	29/847	(3.4)	15/841	(1.8)	0.52 (0.28–0.97)	0.035	28/800	(3.5)	14/803	(1.7)	0.50 (0.26–0.94)	0.028
P. falciparum	25	(3.0)	15	(1.8)	0.60 (0.32–1.14)	0.115	24	(3.0)	14	(1.7)	0.58 (0.30–1.12)	0.098
P. vivax	1	(0.1)	0	(0.0)	–	–	1	(0.1)	0	(0.0)	–	–
Cord blood (light microscopy)^a	4/744	(0.5)	3/744	(0.4)	0.75 (0.17–3.34)	1.000	4/695	(0.6)	3/716	(0.4)	0.73 (0.16–3.24)	0.681
Placental malaria (histology)
Active and past infection^b	150/736	(20.4)	128/736	(17.4)	0.85 (0.69–1.06)	0.143	138/697	(19.8)	122/702	(17.4)	0.88 (0.71–1.10)	0.245
Active infection^c	65/736	(8.8)	44/736	(6.0)	0.68 (0.47–0.98)	0.037	62/697	(8.9)	41/702	(5.8)	0.66 (0.45–0.96)	0.029
Anaemia (Hb <11 g/dL)	689/935	(73.7)	700/933	(75.0)	1.02 (0.97–1.07)	0.508	647/883	(73.3)	663/889	(74.6)	1.02 (0.96–1.08)	0.532
Severe anaemia (Hb <7 g/dL)	44/935	(4.7)	37/933	(4.0)	0.84 (0.55–1.29)	0.432	39/883	(4.4)	34/889	(3.8)	0.87 (0.55–1.36)	0.531

ISSN: 1741-7015